OBiO Technology will showcase at American Society of Gene & Cell Therapy
-Visit OBiO Tech booth #1644 at American Society of Gene & Cell Therapy in Maryland,USA SHANGHAI, April 28, 2024 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase...
OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product
Visit OBiO at ESGCT 30th Annual Congress in Brussels SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene...
OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products
SHANGHAI, April 29, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboration with CHINAGENE. Under the agreement, OBiO will provide holistic contract development and manufacturing services to CH...
A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology
SHANGHAI, April 24, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. ("OBiO" or "the Company"), a leading gene and cell therapy CDMO inChina, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in theChina (Shang...
FDA Accepts GMP Plasmid DMF of OBiO Technology
SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development and manufacturing organization (CDMO), recently announced that the United States Food and Drug Administ...
OBiO Technology to Present Data on OVersatile™ Platform for Process Development of Herpes Simplex Virus and Vaccinia Virus Products at the 25th ASGCT Annual Meeting
SHANGHAI, May 9, 2022 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', SSE:688238.SH), a gene and cell therapy-focused biotechnology company, serving as a contract research organization for vectorology and functional genomics studies, and providing contract development and manuf...
OBiO Technology Goes Public on Shanghai Stock Exchange Today
SHANGHAI, March 22, 2022 /PRNewswire/ -- On March 22, 2022, OBiO Technology ( Shanghai) Corp., Ltd. ("OBiO" or "the Company"), has completed its initial public offering ("IPO") process and started trading on the Shanghai Stock Exchange's Sci-Tech innovation board (SSE, code: 688238). Founded in 2...
